Robert Figlin

Dept of Oncology, University of California, Los Angeles, United States of America

Robert Figlin, M.D.

Academic positions:
- Associate Director for Clinical Research, Comprehensive Cancer Center
- Chair, Division of Medical Oncology & Therapeutics Research
- Arthur and Rosalie Kaplan Professor of Medical Oncology
- Dr Figlin served for 10 years as the Director of the UCLA Hematology/Oncology Fellowship Program until stepping down in 2004.

All industry positions (in last five years):
He is a Scientific Founder of Agensys, a California biotechnology company focusing on targeted therapy of cancer.

Research interests:
Dr Figlin is a Senior Investigator in Translational Research with more than 20 years of expertise in designing & conducting clinical trials in lung & kidney cancer. He is the Co-Principal Investigator & the Director of the Clinical Core for the NCI funded phase III chemoprevention trial, investigating green tea phenol extract, erlotonib, an EGFR receptor antagonist in superficial bladder cancer. Dr Figlin has performed clinical investigations as a Principal Investigator in phase I, II & III trials focusing on cell, immune, genetic & target-based therapy in solid tumor oncology.

Any other information:
He has served as a past faculty member of the ASCO/AACR Methods in Clinical Research Meeting held annually in Vail, Colorado. Professional Memberships;
Fellow, American College of Physicians American Society of Clinical Oncology UCLA's Jonsson Comprehensive Cancer Center American Association for Cancer Research Fellow, International Society for Biologic Therapy International Association for the Study of Lung Cancer Association of Subspecialty Professors American Urological Association

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Oncology > Genitourinary Cancers (since 15 November 2005)

Links

http://www.uclakidney.com

All recent recommendations

• 3.0
  A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
  Recommended by Robert Figlin with Dr Przemyslaw Twardowski
  
• 3.0
  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
  Recommended by Robert Figlin
  
• 3.0
  Sunitinib in patients with metastatic renal cell carcinoma.
  Recommended by Robert Figlin